Performance for
OA knee pain reduction
that matters

Woman kicking in three positions

Powerful pain reduction

OA knee-pain reduction to help you
perform everyday activities

After 3 injections,
patients had
significantly less
pain associated with
5 basic functions

Climbing Stairs
Climbing Stairs
Standing
Standing
Walking
Walking
Sitting
Sitting
Resting during night
Resting
during night

The effectiveness and safety of EUFLEXXA was shown to be comparable to another HA product in a head-to-head clinical trial. The study was conducted in 321 patients with
OA knee pain over a 12-week period.*

Pain improvement with EUFLEXXA was 62% (P<0.0001) vs 55% with the other product (P<0.0001).†

Most common adverse events include joint pain (11/160), increase in blood pressure (3/160), joint swelling (3/160), feeling of sickness (3/160), tingling (2/160), back pain (1/160), nausea (1/160), skin irritation (1/160).

Nearly 2 out of 3 patients were pain-free at the end of a 12-week study

HA=hyaluronic acid; OA=osteoarthritis.

*Questions based on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). WOMAC is an internationally recognized and widely used set of standardized questionnaires that allow healthcare providers to assess the condition of patients with osteoarthritis of the knee and hip. Measures include pain, stiffness, and physical functioning of the joints.

†Improvements from baseline were statistically significant for both treatment groups. EUFLEXXA = (101/160)

‡ Based on % reduction in WOMAC pain score from baseline in a pivotal, 12-week trial of EUFLEXXA (n=157) vs Synvisc (n=158). Pain-free defined as symptom-free for the 5 WOMAC pain questions (with average visual analog scale [VAS] scores of <20 mm).

Less OTC pain medicine

EUFLEXXA helped patients
avoid pain medication.†

In a clinical trial, significantly fewer unilateral*
patients treated
with EUFLEXXA
had a need for acetaminophen vs another
HA (P=0.001).

~3x more EUFLEXXA patients avoided rescue medication compared to a leading HA*
~3x more EUFLEXXA patients avoided rescue medication compared to a leading HA*
Don't let OA knee pain hold you back. Ask your doctor if Euflexxa is right for you.

HA=hyaluronic acid; OA=osteoarthritis.

Acetaminophen was the only additional medication provided.

*Unilateral means OA knee pain in one knee.

†EUFLEXXA 51% (34 of 67 patients with unilateral knee pain)
another HA 18% (13 of 72 patients with unilateral knee pain).

Satisfying results

Performance you can believe in

In a 12-week clinical trial more than 8 out of 10 Euflexxa ptients were satisfied with the reduction of OA knee pain. In a 12-week clinical trial more than 8 out of 10 Euflexxa ptients were satisfied with the reduction of OA knee pain. Avatar of people outlined.
>5 million patients treated with EUFLEXXA in the US

OA=osteoarthritis.

*In the 12-week study, side effects caused by EUFLEXXA were
joint pain (11/160), increase in blood pressure
(3/160), joint
swelling (3/160), feeling of sickness (3/160), tingling (2/160),
back pain (1/160), nausea (1/160), skin irritation (1/160), and tenderness in study knee (1/160).

Learn how easy it is to get started with EUFLEXXA

1. #1 prescribed HA is based on rolling 12-month average of IQVIA claims data from unique patients (November 2021).

2. Kirchner M, Marshall D. A double-blind randomized controlled trial comparing alternate forms of high molecular weight hyaluronan for the
treatment of osteoarthritis of the knee. Osteoarthritis Cartilage. 2006;14(2):154-162.

2. Data on file. Ferring Pharmaceuticals Inc.

Please see Important Safety Information and Full Prescribing Information

Open
Close

INDICATION

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

IMPORTANT SAFETY INFORMATION

  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

Please see Important Safety Information and Full Prescribing Information

INDICATION

EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used for patients who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

EUFLEXXA is only for injection into the knee, performed by a doctor or other qualified healthcare professional.

IMPORTANT SAFETY INFORMATION

  • Do not take this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products.
  • You should not have EUFLEXXA injected into the knee if you have a knee joint infection or skin diseases or infections around the injection site.
  • EUFLEXXA has not been tested in pregnant women, women who are nursing or in children less than 18 years of age. After you receive your EUFLEXXA injection you should avoid physical activities for 48 hours such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour at a time).
  • The most common adverse events related to EUFLEXXA injections were joint pain, back pain, limb pain, muscle pain, and joint swelling.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

abstract
Video Play button play-icon

Find a healthcare provider near you who treats knee pain with EUFLEXXA®.

Find a Doctor >

See How Jan Managed Osteoarthritis Knee Pain with EUFLEXXA® (1% sodium hyaluronate)

Watch Jan’s story on this segment of The Balancing Act airing on Lifetime TV

When dog trainer Jan first experienced knee pain, she tried treating it on her own for some time, but the pain became too much for her to bear. Learn how she managed this debilitating condition with the help of her doctor and EUFLEXXA®. Click to play the video and find out if EUFLEXXA® may be right for you!

PLEASE SEE IMPORTANT SAFETY INFORMATION AND FULL PRESCRIBING INFORMATION

US-EU-2200046